Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Evaluate the Efficacy and Safety of Brightening Micro-needle Patch on Facial Solar Lentigines
- Conditions
- Solar Lentigines
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04583852
- Locations
- 🇨🇳
Department of Dermatology, National Taiwan University, Taipei, Taiwan
PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT04543812
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
🇨🇳Taipei Municipal Wanfang Hospital, Taipei, Taiwan
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Conditions
- ESRDHyperphosphatemiaEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT03984760
- Locations
- 🇨🇳
Baotou Central Hospital, Baotou, China
🇨🇳The General Hospital of the People's Liberation Army (PLAGH), Beijing, China
🇨🇳The Second Hospital of Jilin University, Changchun, China
Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis
- Conditions
- Kidney Failure, ChronicEnd-stage Renal DiseaseHyperphosphatemiaPhosphorus Metabolism Disorders
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT03256838
- Locations
- 🇨🇳
Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
- Conditions
- HyperphosphatemiaEnd Stage Renal DiseaseESRD
- Interventions
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Panion & BF Biotech Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT01503736
- Locations
- 🇨🇳
Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan
🇨🇳Division of Nephrology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
🇨🇳Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital, New Taipei City, Taiwan
News
EMA Recommends Approval of Averoa's XOANACYL for Chronic Kidney Disease Treatment
The European Medicines Agency's CHMP has issued a positive opinion for XOANACYL, an oral therapy for chronic kidney disease, with final European Commission approval expected by June 2025.